Clinical Trials Logo
  1. Home
  2. CML
  3. NCT05152537

FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia — NTU-CML-001  

CML Clinical Trial

Official title:
A Multicenter Prospective Cohort Study of FLOR3 Gene Polymorphism in Predicting Outcomes of TKI-stopping in Chronic Myeloid Leukemia

Clinical Trial Summary

For patients with chronic myeloid leukemia in chronic phase (CML-CP) who have achieved a stable deep molecular response (DMR) using BCR-ABL1 tyrosine kinase inhibitors (TKIs), treatment-free remission (TFR) following TKI cessation is an emerging goal. However, about half of the patients relapsed after TKI discontinuation. There is no definite examinations to predict the outcome of TKI discontinuation. Investigators aim to study the relationship between FLOR3 SNP rs139130389 and the outcome of TKI discontinuation.

Clinical Trial Description

Investigators aim to detect FOLR3 SNP rs139130389, and establish its correlation with patients' treatment response, remission time, TKI resistance and the outcome of TKI stopping. ;

Study Design

Related Conditions & MeSH terms

  • CML
  • Folate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clinical Trial Details
NCT number NCT05152537
Study type Observational
Source Affiliated Hospital of Nantong University
Contact Hong Liu, Doctorate
Phone +8613951300660
Email hongliu63@126.com
Status Recruiting
Phase
Start date January 1, 2021
Completion date December 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Terminated NCT01131325 - Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Phase 4
Active, not recruiting NCT03578367 - Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Phase 2
Completed NCT03747679 - Palatability (Taste) of Oral Formulations of Bosutinib Phase 1
Completed NCT01019317 - Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) Phase 2
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Completed NCT03880617 - Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy
Completed NCT00858572 - STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders Phase 1
Completed NCT00684008 - Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant Phase 1
Completed NCT00013533 - Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies Early Phase 1
Not yet recruiting NCT06047886 - CD34 Selection Using the Automated CliniMACS Prodigy Phase 1
Recruiting NCT05823571 - Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Phase 1
Completed NCT00780104 - Sirolimus in Combination With MEC in High Risk Myeloid Leukemias Phase 1
Recruiting NCT06211166 - Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
Recruiting NCT01762969 - Treatment Modification Based on Early Assessment of CML Patients Phase 2
Completed NCT00891592 - Umbilical Cord Blood Transplant for Hematological Malignancies Phase 1
Terminated NCT00776373 - Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies Phase 1/Phase 2
Completed NCT00511537 - Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders N/A
Completed NCT03678454 - Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
Completed NCT01206088 - Tasigna in Glivec-resistant or Intolerant Patients in CML Phase 4